In addition to full-field digital mammography and titanium contrast-enhanced mammography capabilities, the Mammomat B.brilliant system also offers ergonomic, workflow and patient comfort benefits.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Mammomat B.brilliant, a redesigned mammography device that reportedly features improved ergonomics, workflow enhancements and key aspects targeting patient comfort.
The system’s laser positioning guide and curved breast compression paddles facilitate optimal breast positioning and improved consistency with image quality, according to Siemens Healthineers, the manufacturer of Mammomat B.brilliant. To further address the bending and twisting that can occur with patient positioning, the company said the automated ComfortMove feature with the Mammomat B.brilliant system allows tube head movement that is independent of the bucky.
Siemens Healthineers said the system also features cleared elements with respect to full-field digital mammography, titanium contrast-enhanced mammography (CEM) and breast biopsy procedures.
“With the 510(k) clearance of the Mammomat B.brilliant, Siemens Healthineers proudly introduces completely new mammography technology to the market,” said Niral Patel, vice president of X-ray products at Siemens Healthineers North America. “We believe more women deserve access to next-generation screening technology, and this innovation underlies our commitment to women’s health.”
Another feature, PlatinumTomo, a 3D tomosynthesis volume acquisition technology, is pending FDA review, according to Siemens Healthineers. The company added that the PlatinumTomo feature is currently available in Asia, Europe, and South America.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.